Indivior Pharmaceuticals, Inc.

(c)During the quarter ended March 31, 2026, three officers or directors adopted Rule 10b5-1 trading plans intended to satisfy the affirmative defense of Rule 10b5-1(c): (i)Jeffrey Burris, Chief Legal Officer, adopted a plan on March 13, 2026, covering 50,000 shares to be sold under the plan, that expires at the close of business on March 4, 2027; (ii)Christian Heidbreder, Chief Scientific Officer, adopted a plan on March 13, 2026, covering 55,758 shares to be sold under the plan, that expires at the close of business on August 31, 2026; and (iii)Ryan Preblick, Chief Financial Officer, adopted a plan on March 6, 2026, covering 36,000 shares to be sold under the plan, that expires at the close of business on October 30, 2026.

In connection with the Convertible Notes Offering, each of these persons entered into customary "lock-up" agreements in favor of the Company's investment bankers which prohibit these insiders from, among other things, selling any Company shares until after May 11, 2026; notwithstanding the entry into the 10b5-1 plans, no sales will be made until after May 11, 2026.